Company
Hangzhou DAC Biotechnology Co., Ltd.
Hangzhou DAC Biotechnology Co., Ltd. has 1 drug tracked on RxWires: 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Cohort A: DXC016 dose escalation | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow Hangzhou DAC Biotechnology Co., Ltd. on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.